Cold Atmospheric Pressure Plasma in the Treatment of Diabetic Foot Ulcers: A Systematic Review

冷大气压等离子体治疗糖尿病足溃疡:系统评价

阅读:1

Abstract

Cold atmospheric pressure plasma (CAPP) is an innovative energy-based therapy which has gained momentum in recent years for its wide array of therapeutic applications. This systematic review aims to evaluate the effectiveness and safety of CAPPs in treating diabetic foot ulcers. We conducted systematic literature searches on Embase, Ovid Medline, Scopus, Cochrane Central Register of Controlled Trials, The Cochrane Database of Systematic Reviews and Clinicaltrials.gov using PRISMA guidelines. We searched for randomised controlled trials (RCTs) and observational studies conducted on patients with diabetic foot ulcers in which CAPP therapy was compared with a control treatment. The risk of bias was assessed using the Cochrane Collaboration tool. Four RCTs from two countries analysing a total of 153 patients were included in the review. Three studies reported a significant reduction in ulcer area in the CAPP group, one study reported a significant decrease in inflammatory markers, and mixed results were reported regarding the reduction of bacterial load. All studies reported no adverse side effects or concerns with the safety profile of CAPP. Current evidence supports CAPP's potential as safe and effective adjunctive therapy that may accelerate wound healing, reduce wound size, promote tissue regeneration and lower infection risks. However, the limited number and size of trials, variability in treatment protocols and short follow-up periods highlight the preliminary nature of these findings. Further large-scale, well-designed studies with standardised protocols and long-term follow-up are needed to confirm CAPP's efficacy and safety, as well as to determine its cost-effectiveness in diverse healthcare settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。